Sphere Fluidics is a privately held company based in Babraham, Cambridge, UK that commercializes single cell analysis systems. The company was originally spun out from the University of Cambridge and has 32 patented products including, instruments, software, biochips, and specialist chemicals.
Sphere Fluidics' main products are Cyto-Mine and ESI-Mine. Cyto-Mine was introduced in September 2018. It is an automated platform which integrates single cell screening, sorting, isolation, and clone verification. The product is meant to work alongside industry-standard robotic platforms and corporate databases to improve antibody discovery and cell line development workflows. ESI-Mine is a platform that can be used for high-throughput mass spectometry (MS) analysis. It enables the retrieval of living copies of hits that are normally destroyed during MS procedures.
Sales and Marketing Director, North America
Frank F. Craig
Director & CEO
VP, Research and Development
Global Distribution Manager
VP, Sales and Marketing
Director of Operations
Documentaries, videos and podcasts